恩格列净改善糖尿病前期患者下丘脑胰岛素敏感性:随机双盲安慰剂对照2期试验
该随机双盲安慰剂对照2期试验纳入40例糖尿病前期患者,随机接受恩格列净25 mg每日一次或安慰剂治疗8周,用功能MRI结合鼻内胰岛素给药评估下丘脑胰岛素敏感性。结果显示仅恩格列净组下丘脑胰岛素反应性增加,且下丘脑胰岛素作用介导了恩格列净引起的空腹血糖和肝脏脂肪下降。
要点
- 恩格列净治疗8周可恢复糖尿病前期患者下丘脑胰岛素敏感性
- 下丘脑胰岛素作用介导恩格列净降低空腹血糖和肝脏脂肪
- SGLT2抑制可能是逆转脑胰岛素抵抗的首个药物途径
核心结论
- 恩格列净治疗8周能恢复糖尿病前期患者的下丘脑胰岛素敏感性,该反应可能有助于SGLT2抑制剂的获益。
研究设计与样本
- 随机、双盲、安慰剂对照的2期临床试验,纳入40例糖尿病前期患者(平均年龄60±9岁,BMI 31.5±3.8 kg/m2)。
- 患者随机接受恩格列净25 mg每日一次或安慰剂治疗8周,治疗前后用功能MRI结合鼻内胰岛素给药评估脑胰岛素敏感性。
主要发现
- 下丘脑对胰岛素的反应存在显著的时间与治疗交互作用。
- 事后分析显示仅恩格列净组患者下丘脑胰岛素反应性增加。
- 下丘脑胰岛素作用显著介导了恩格列净引起的空腹血糖和肝脏脂肪下降。
临床怎么用
- 对糖尿病前期患者,恩格列净可能通过改善下丘脑胰岛素敏感性带来代谢获益。
- 下丘脑胰岛素抵抗可作为SGLT2抑制剂作用机制的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Insulin action in the human brain reduces food intake, improves whole-body insulin sensitivity, and modulates body fat mass and its distribution. Obesity and type 2 diabetes are often associated with brain insulin resistance, resulting in impaired brain-derived modulation of peripheral metabolism. So far, no pharmacological treatment for brain insulin resistance has been established. Since sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glucose levels and modulate energy metabolism, we hypothesized that SGLT2 inhibition may be a pharmacological approach to reverse brain insulin resistance. RESEARCH DESIGN AND METHODS: In this randomized, double-blind, placebo-controlled clinical trial, 40 patients (mean ± SD; age 60 ± 9 years; BMI 31.5 ± 3.8 kg/m2) with prediabetes were randomized to receive 25 mg empagliflozin every day or placebo. Before and after 8 weeks of treatment, brain insulin sensitivity was assessed by functional MRI combined with intranasal administration of insulin to the brain. RESULTS: We identified a significant interaction between time and treatment in the hypothalamic response to insulin. Post hoc analyses revealed that only empagliflozin-treated patients experienced increased hypothalamic insulin responsiveness. Hypothalamic insulin action significantly mediated the empagliflozin-induced decrease in fasting glucose and liver fat. CONCLUSIONS: Our results corroborate insulin resistance of the hypothalamus in humans with prediabetes. Treatment with empagliflozin for 8 weeks was able to restore hypothalamic insulin sensitivity, a favorable response that could contribute to the beneficial effects of SGLT2 inhibitors. Our findings position SGLT2 inhibition as the first pharmacological approach to reverse brain insulin resistance, with potential benefits for adiposity and whole-body metabolism.
引用
- Kullmann S, Hummel J, Wagner R, et al. Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. Diabetes Care. 2022. PMID: 34716213. doi:10.2337/dc21-1136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。